Search

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company Statement on the ADA Request for Independent Review of Incretin-Based Therapies

Jardiance® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events

Boehringer Ingelheim Partners with Express Scripts on their Patient Assurance Program Expansion for People with Type 2 Diabetes

Niha Agarwalla

My career challenge at Boehringer Ingelheim by Niha Agarwalla. Read it now!

BI Awards Showcase Veterinary Talent | Boehringer Ingelheim US

Click here to read more on the Boehringer Ingelheim annual awards showcasing and celebrating emerging veterinary talent across the USA.

Novel antibody shows potential to transform treatment of rare form of psoriasis

Boehringer Ingelheim and Click Therapeutics Expand their Existing Collaboration to Develop Prescription Digital Therapeutics for Schizophrenia

Boehringer Ingelheim announces comprehensive settlement of U.S. Pradaxa® (dabigatran etexilate mesylate) litigation

BI Starts Clinical Study on Interchangeability | Boehringer Ingelheim US

BI announced today that the first patient has been enrolled into its VOLTAIRE-X interchangeability study, for an adalimumab biosimilar candidate.

Boehringer Ingelheim and Vanderbilt University Expand Partnership to Develop Novel Treatment Approaches for Cancer

Ridgefield, Connecticut, home to our U.S. headquarters, is ranked #1 safest place to live

Read about what makes Ridgefield, Connecticut a great place to live, work, and make a difference in the lives of people and animals.

Country Management Committee: A Message | Boehringer Ingelheim US

Click here to read a statement from Boehringer Ingelheim on the tragic events in Uvalde, TX and how BI Cares is supporting victims and families.

First Patient Enrolled in New Cardiovascular and Renal Outcomes Trial for TRADJENTA® (linagliptin) Tablets in Type 2 Diabetes

New Jardiance® (empagliflozin) data show improved CV outcomes regardless of heart failure status at baseline

FDA Approves Pradaxa® (dabigatran etexilate mesylate) for Treatment and Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism

Accessibility Statement

Boehringer Ingelheim endeavors to make https://www.boehringer-ingelheim.com accessible to any and all users.

Cyltezo® (adalimumab-adbm) Patent Litigation Resolution| BI US

Read more about Boehringer Ingelheim's CYLTEZO patent litigation resolution, meaning greater access to the treatment for patients across the USA.

Boehringer Ingelheim caps patient out-of-pocket costs for its inhaler portfolio at $35 per month

Boehringer Ingelheim cap out-of-pocket costs at $35 per month for eligible patients for all of the company’s inhaler products.

BI & Lilly to Assess Jardiance® (empagliflozin) & Heart Failure | Boehringer Ingelheim US

Read more on the 1st ever study to assess JARDIANCE in people with heart failure who have been stabilized. View ISI, PI and Med Guide.

Linagliptin Demonstrated Significant HbA1c Reduction in Elderly People With Type 2 Diabetes With Inadequate Glycemic Control

Jardiance® (empagliflozin) to be studied for the treatment of people with chronic heart failure

FDA Advisory Committee Recommends Approval of Tiotropium Respimat® for the Maintenance Treatment of COPD

Leadership insights about our focus on patient centricity

Read about our patient-centric approach in discovering and developing medicines that transform patients’ lives from the point of view of Keri Yale, our head of patient centricity and engagement

FDA Approves Pradaxa® (dabigatran etexilate) for DVT & PE | BI US

FDA approves PRADAXA for the prophylaxis of DVT & PE in patients who have undergone a hip replacement. View ISI, PI and Med Guide.

Boehringer Ingelheim Presents First Head-to-Head Matched Population Comparison

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers